Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes.

[1]  J. H. Patterson,et al.  Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. , 2021, Journal of cardiac failure.

[2]  A. Clark,et al.  Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure , 2021, Clinical Research in Cardiology.

[3]  J. Rouleau,et al.  Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? , 2020, JACC. Heart failure.

[4]  J. Januzzi,et al.  Heart Failure With Reduced Ejection Fraction: A Review. , 2020, JAMA.

[5]  J. Barbetseas,et al.  Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients , 2020, Heart Failure Reviews.

[6]  W. Heggermont,et al.  Clinical inertia in the treatment of heart failure: a major issue to tackle , 2020, Heart Failure Reviews.

[7]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[8]  A. Cohen-Solal,et al.  Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients , 2020, European journal of heart failure.

[9]  K. Anstrom,et al.  Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. , 2020, JAMA cardiology.

[10]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[11]  M. Metra,et al.  Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach , 2019, Drugs.

[12]  G. Grassi,et al.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options , 2019, Heart Failure Reviews.

[13]  J. H. Patterson,et al.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[14]  Adrian F Hernandez,et al.  Heart failure drug treatment , 2019, The Lancet.

[15]  H. Brunner-La Rocca,et al.  Loop diuretics in chronic heart failure: how to manage congestion? , 2018, Heart Failure Reviews.

[16]  J. Spertus,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[17]  R. McKelvie,et al.  2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.

[18]  P. Ponikowski,et al.  Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.

[19]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2017, European journal of heart failure.

[20]  L. Stevenson,et al.  The Future of Heart Failure Diagnosis, Therapy, and Management. , 2016, Circulation.

[21]  R. McKelvie,et al.  The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. , 2016, The Canadian journal of cardiology.

[22]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[23]  A. Hallas,et al.  Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. , 2014, International journal of cardiology.

[24]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[25]  P. Ponikowski,et al.  EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) , 2010, European journal of heart failure.

[26]  J. Rumsfeld,et al.  Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? , 2010, Circulation. Cardiovascular quality and outcomes.

[27]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[28]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[29]  I. Proskorovsky,et al.  The morbidity and mortality following a diagnosis of peripheral arterial disease: Long-term follow-up of a large database , 2005, BMC cardiovascular disorders.

[30]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[31]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.